Related Experiment Video
Updated: Jan 30, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation
Myrto Lee1, Hoan Ly2, Clemens C Möller3
1The Boston Consulting Group, London, UK.
Abstract:
At the turn of the century, the pharmaceutical industry began a transition toward a focus on oncology, rare diseases, and other areas of high unmet need that required a new, more complex approach to drug development. For many of these disease states and novel approaches to therapy, traditional approaches to clinical trial design fall short, and a number of innovative trial designs have emerged. In light of these changes, regulators across the globe are implementing new programs to provide regular development program support, facilitate accelerated access, use real-world data, and use digital tools to improve patients' lives. Emerging market regulators are also focusing on simplifying their regulatory pathways via regional harmonization schemes with varying levels of ambition. These changes in the external environment imply that biopharma regulatory teams need to adapt and evolve, leveraging digital tools, data, and analytics, and positioning themselves as strategic advisors during development.
Insights
The pharmaceutical industry is shifting towards complex drug development for oncology and rare diseases. Regulatory bodies are adapting with new programs and digital tools to support innovation and patient access.
Area of Science:
- Pharmaceutical industry evolution
- Drug development innovation
- Regulatory science
Background:
- Shift towards oncology, rare diseases, and high unmet needs
- Traditional clinical trial designs are insufficient for novel therapies
- Emergence of innovative clinical trial designs
Purpose of the Study:
- Analyze the evolving landscape of drug development and regulatory affairs
- Highlight the impact of new therapeutic areas and trial designs
- Examine regulatory adaptations and their implications for biopharma teams
Main Methods:
- Review of industry trends and regulatory changes
- Analysis of innovative clinical trial designs
- Assessment of global regulatory initiatives (e.g., real-world data, digital tools, accelerated access)
Main Results:
- Global regulators are implementing supportive programs and digital tools
- Emerging markets are simplifying regulatory pathways through harmonization
- Biopharma regulatory teams must adapt to leverage data and analytics
Conclusions:
- The biopharmaceutical industry requires adaptive regulatory strategies
- Digital tools and real-world data are crucial for modern drug development
- Regulatory teams need to evolve into strategic advisors for development programs
Related Concept Videos
The Evidence for Evolution
Convergent Evolution
Cis-regulatory Sequences
Cis-regulatory Sequences
Psychology as a Science
The scientific method in psychology involves six critical steps: making observations, formulating hypotheses, conducting tests, analyzing...
Gene Evolution - Fast or Slow?
In contrast, regions which code...

